FDA Matters logo
  • Blog
  • About
  • Media
New CBER Leadership: The FDA Matters Analysis

New CBER Leadership: The FDA Matters Analysis

by Steven A. Grossman | May 8, 2025 | Short Takes and Updates

The headline, “Dr. Prasad to succeed Peter Marks as CBER director,” spread like wildfire Tuesday night after Endpoints News broke the story. Reactions ranged from “Omigod, he’ll destroy the industry and the hopes of patients” to “no big deal, staff do the product...
New CBER Leadership: The FDA Matters Analysis

Truth-Telling: FDA User Fee Edition

by Steven A. Grossman | May 2, 2025 | Short Takes and Updates

After 50 years in Washington, I have no expectation of being told the truth by government officials—elected or appointed. I like to think I have seen it all—shading the truth, burying the truth, plausibly deniable truth, and sometimes things entirely made up and...
New CBER Leadership: The FDA Matters Analysis

The American People in the Hands of an Indifferent Government

by Steven A. Grossman | Apr 29, 2025 | Short Takes and Updates

Several decades ago, when I was a Senate staffer, I observed that I could spend the entire Gross Domestic Product on the good ideas that people brought to us. I soon learned that lawmaking requires a substantial amount of restraint and a lot of prioritizing. Those are...
New CBER Leadership: The FDA Matters Analysis

How Many People Still Work for FDA & Other FDA Thoughts

by Steven A. Grossman | Apr 25, 2025 | Short Takes and Updates

FDA’s responsibilities have not changed since January 20th. However, its capacity to carry out its duties has been meaningfully reduced by the Administration’s downsizing. We should all be able to agree on that. It has not been clear how many people still work...
New CBER Leadership: The FDA Matters Analysis

FDA and Politics: An Unhealthy Combination

by Steven A. Grossman | Apr 22, 2025 | Short Takes and Updates

Dr. Makary is a physician, healthcare quality and outcomes researcher, and self-styled iconoclast. When he accepted the Commissioner position in November 2024[1], I am sure he believed that Trump 2.0 would be a hospitable place to harness those personal attributes in...
« Older Entries
Next Entries »

Recent Posts

  • New Op-Ed: Here’s How the Blue Tsunami Will Turn the Healthcare Tide
  • Public Health and the Midterm Elections– A Field Guide
  • Can the Midterms Save Vaccines? Don’t Count on It.
  • Leading FDA Is an Impossible Job Right Now. Heidi Overton Could Still Do It Well.
  • Chairman Cassidy: Please Ask Dr. Overton About FDA Decision-Making

Recent Comments

No comments to show.
FDA Matters logo

 ©2009-2026 FDA Matters | FDA Matters does not report the news….we provide analysis of what’s behind the news.

We sometimes use artificial intelligence in drafting columns, primarily using Claude AI and Microsoft Co-Pilot. We review and verify all findings, interpretations, and final wording.